|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
LEIRAS PHARMCEUTICAL HUTAMAKI OY
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
C
|
|
INDICATIONS:
|
|
Asthma |
|
Bronchospasm, exercise- induced |
| |
|
|
SIDE EFFECTS:
|
|
Palpitation |
|
tachycardia |
|
Adams-Stokes attacks |
|
allergic reactions |
|
angioedema |
|
bronchospasm |
|
oropharyngeal edema |
|
skin rash |
|
urticaria |
|
bronchospasm, paradoxical |
|
cardiac arrhythmias |
|
chest pain |
|
hypokalemia |
|
severe reaction |
|
erythema multiforme |
|
Stevens-Johnson syndrome |
|
hypertension |
|
psychoneurotic disorders |
|
psychomotor agitation |
|
disorientation |
|
impairment of memory |
|
assaultive behavior |
|
panic |
|
hallucinations |
|
suicidal or homicidal tendencies |
|
schizophrenic-type thought disorder |
|
paranoid delusions |
|
seizures |
|
urinary hesitation or retention |
|
Anxiety |
|
headache |
|
nervousness |
|
tremor |
|
Dizziness |
|
insomnia |
|
muscle cramps |
|
nausea |
|
sweating |
|
vertigo |
|
vomiting |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
Cardiac arrhythmias |
|
>> Coronary insufficiency |
|
Hypertension, not optimally controlled |
|
Hyperthyroidism, not optimally controlled |
|
Pheochromocytoma, diagnosed or suspected |
|
>> Sensitivity to an adrenergic bronchodilator |
|
|
ADULT DOSE:
|
|
Bronchodilator-Oral inhalation, 2 inhalations (180 or 200 mcg albuterol) every four to six hours. For some patients, 1 inhalation (90 or 100 mcg) every four to six hours may be sufficient.
Bronchospasm, exercise-induced (prophylaxis) -Oral inhalation, 2 inhalations (180 or 200 mcg) fifteen minutes prior to exercise . |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Bronchodilator-Children up to 4 years of age: Dosage has not been established.
Children 4 years of age and over: See Usual adult and adolescent dose. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|